Wuhan YZY Biopharma Co (HKSE:02496) Beginning Cash Position: HK$183.58 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02496 Wuhan YZY Biopharma Co Ltd HKSE:02496
20 GF Score
Price HK$3.30
! 8 Warning Signs
View Full Analysis

What is Wuhan YZY Biopharma Co Beginning Cash Position?

Wuhan YZY Biopharma Co HKSE:02496 20 Beginning Cash Position is HK$183.58 Mil as of Dec. 2025. GuruFocus rates HKSE:02496 with a GF Score™ of 20/100. The stock has 8 warning signs investors should review.

Wuhan YZY Biopharma Co's Beginning Cash Position for the quarter that ended in Dec. 2025 was HK$183.58 Mil.

Wuhan YZY Biopharma Co's quarterly Beginning Cash Position declined from Dec. 2024 (HK$174.89 Mil) to Jun. 2025 (HK$138.03 Mil) but then increased from Jun. 2025 (HK$138.03 Mil) to Dec. 2025 (HK$183.58 Mil).

Wuhan YZY Biopharma Co's annual Beginning Cash Position increased from Dec. 2023 (HK$167.92 Mil) to Dec. 2024 (HK$209.99 Mil) but then declined from Dec. 2024 (HK$209.99 Mil) to Dec. 2025 (HK$139.50 Mil).

Wuhan YZY Biopharma Co Beginning Cash Position Related Terms

Wuhan YZY Biopharma Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Wuhan YZY Biopharma Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan YZY Biopharma Co Beginning Cash Position Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
147.79 92.78 167.92 209.99 139.50

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only 211.74 174.89 138.03 183.58 0.00
HKSE:02496
20GF Score
Wuhan YZY Biopharma Co Ltd HKSE:02496
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan YZY Biopharma Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of HK$183.58 Mil mean?
Wuhan YZY Biopharma Co (HKSE:02496) has a Beginning Cash Position of HK$183.58 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Wuhan YZY Biopharma Co and its competitors.
Is Wuhan YZY Biopharma Co's Beginning Cash Position too high?
Wuhan YZY Biopharma Co's current Beginning Cash Position is HK$183.58 Mil. Overall, Wuhan YZY Biopharma Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan YZY Biopharma Co's Beginning Cash Position compare to VRTX and REGN?
Wuhan YZY Biopharma Co's Beginning Cash Position of HK$183.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Wuhan YZY Biopharma Co and its competitors. Wuhan YZY Biopharma Co's current Beginning Cash Position is HK$183.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current Beginning Cash Position of HK$183.58 Mil. The current Beginning Cash Position is HK$183.58 Mil. Wuhan YZY Biopharma Co's overall GF Score™ is 20/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current Beginning Cash Position is HK$183.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan YZY Biopharma Co Business Description

Address No. 666 Gaoxin Road, Building C2-1, Optics Valley Bio-City, East Lake High Tech Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
20GF Score

Get the complete analysis for HKSE:02496

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.30
Price